Ladies and gentlemen, thank you for standing by for Zepp Health Corporation's fourth quarter and full year 2021 earnings conference call. At this time, all participants are in listen-only mode. Today's conference call is being recorded. I will now turn the call over to your host, Ms. Grace Zhang, Director of Investor Relations for the company. Please go ahead, Grace.
Hello, everyone, and welcome to Zepp Health Corporation's fourth quarter and full year 2021 earnings conference call. The company's financial and operating results were issued in a press release via Newswire Services earlier today and are posted online. You can also view the earnings press release and the slides, which we will refer to on this call, by visiting the IR section of the company's website at ir.zepp.com. Participating in today's call are Mr. Wang Huang, our Chairman of the Board of Directors and Chief Executive Officer, and Mr. Leon Cheng Deng, our Chief Financial Officer. The company's management will begin with prepared remarks and the call will conclude with a Q&A session. Before we continue, please note that today's discussion will contain forward-looking statements under the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks and uncertainties.
As such, the company's actual results may be materially different from the views expressed today. Further information regarding this and other risks and uncertainties is included in the company's annual report on Form 20-F for the fiscal year ended December 31, 2020, and other filings as filed with the U.S. Securities and Exchange Commission. The company does not assume any obligation to update any forward-looking statements except as required under applicable law. Please also note that Zepp's earnings press release and this conference call include discussions of unaudited GAAP financial information as well as unaudited non-GAAP financial information. Zepp's press release contains reconciliation of the unaudited non-GAAP measures to the unaudited most directly comparable GAAP measures. I'll now turn the call over to our CEO, Mr. Wang Huang. Please go ahead.
Hello, everyone. Thank you for joining our call. In 2021, we made significant strides despite the challenging macro environment. Our full year revenue reached RMB 6.25 billion as we diligently executed our core growth strategies in the smart consumer health and fitness sector. We maintained our profitability and at the same time grew our self-branded product shipments by 60% during the past year in the face of worldwide chip shortages, as well as the Delta and Omicron COVID variants in the second half of 2021. We are very proud that as of the fourth quarter of 2021, we have cumulatively shipped over 200 million health management devices since our inception. These achievements reflect our increasing global appeal and our dedication to improving our users' lives through technological advancements. Let me expand on our global progress.
The momentum of our overseas expansion remains robust, with over 80% of our self-branded products sold internationally. Notably, our self-branded products shipment volume for the North American region increased by approximately 200% year-over-year as we enter major retail sales channels, including more than 1,000 offline Target stores as well as QVC. As for European markets, our shipments to Italy and France increased by more than 100% in the fourth quarter, thanks to our country-specific strategy. We are now ranked number five in the adult smartwatch market according to the fourth quarter 2021 IDC market data. We have been among the top five in the global market top for several quarters, demonstrating our enhanced product capability and flourishing brand recognition in the growing smartwatch industry.
As we work to enlarge our global footprint, we remain steadfast in our mission to connect health with technology. To the end, we continue to develop priority technologies, including AI chips, biometric sensors and data algorithms to improve user experience and create new usage scenarios as we grow our portfolio of smart health devices for consumers. For example, to further optimize user experience, we will soon launch an AI sleep service to help users with sleeping disorders. Based on our powerful AI algorithms, our Zepp app will compose and recommend high-quality music designed to enhance sleep quality, improving users' sleep hygiene and overall health and wellness. In addition, these algorithms-based user services are playing an integral role in expanding our smart health ecosystem as Zepp Health user base continues to grow, surpassing 40 million active users by the end of 2021.
We are also exploring opportunities in the industrial health segment, including investments in Promaxo and neuro42, which has bolstered our foothold in imaging technology. We enter the portable MRI business to advance the same mission that drives our smart wearable business, to empower our users to quantify their health data, which can assist them in managing health conditions and potentially to help detect earlier warning signs for certain disease. In the future, we plan to integrate these investments along with our data analysis and smart wearable business into our extensive healthcare services, fulfilling a critical need and creating value for our users. Now, turning to our smart wearable business.
Our newly launched GT 3 series smartwatches, which are our first products- incorporating blood pressure measuring functionality, which is currently under review by the NMPA, National Medical Products Administration of China, and we already achieved initial results in this process. They have exceeded our expectation in terms of market recognition and product reviews, and have sold exceptionally well, ranking number one in both JD and Tmall smartwatch category immediately after we commenced sales. In addition, the GT 3 was named Editor's Recommended Smartwatch by Germany's Brigitte magazine. Not only are our smartwatches attracting some consumer attention and acclaim, our other products are also rapidly gaining popularity and industry recognition. For example, our wireless active noise cancellation headset, Amazfit PowerBuds Pro, received an honorary award in the Health and Wellness category at the CES 2022 Innovation Awards.
Our progress in 2021 went far beyond our hardware products. In terms of technology achievements, we unveiled our Huangshan 2s chip in July, the first wearable artificial intelligence processor with dual-core RISC-V architecture. Its superpower core computing performance can support high load calculations such as graphics and UI operations with low power consumption. We also released our Zepp OS in the fourth quarter, one of the industry's most compact and energy-efficient smartwatch operating system at 55 MB, about 1/28, the size of Apple's watchOS 8. Furthermore, Zepp OS serves as the foundation for our open mini program framework, which we envision will comprise thousands of developers and countless mini smartwatch applications. Our goal is to form a comprehensive Zepp OS ecosystem that will empower our users to manage their health more effectively and enjoy their lives to the fullest.
Our strategic partnership with Xiaomi has been fruitful, achieving many impressive milestones over the years. As you may have seen, we rename the Mi Fit app to Zepp Life to optimize the user experience. The Zepp Life app will inherit tens of millions of the Mi Band users and offer them more comprehensive services, such as the sleep service we mentioned earlier. Going forward, the Zepp Life app and Xiaomi Health and Sports app will both serve Mi Band users. Moreover, the Mi Band 7 will be launched this year as expected, and we will further expand our cooperation with Xiaomi from smart band and smart scale products to future chips and sensors. Together with Xiaomi, we look forward to bringing more innovation to all of our users.
I would like to conclude by saying that I'm incredibly proud of our team, which has persevered and excelled against the backdrop of a very challenging two-year period. This obstacle, however, has made us stronger. Today, our brand recognition, along with our sales and distribution outreach, has expanded considerably compared with two years ago. In 2022, we will continue to build our own brands and enhance our product experience as we pursue a path of vertical integration, relentlessly working to strengthen our capabilities in chips, cloud services, algorithms, operating systems, and products. In the meantime, we also extend our reach to other health and medical-related hardware and introduce our brand new health subscription service, which altogether will lead us to a new stage as a company offering comprehensive healthcare solutions and services.
I remain confident in Zepp's future as we continue to lead the industry in technology and product innovation and bring better health through technology to all of our users. Lastly, we are pleased to announce a special cash dividend of $0.025 per ordinary share, or $0.10 per ADS, to thank our shareholders for their ongoing support, as well as the continuation of our share buyback program. We are convinced that as we strive to execute our strategy, we will maximize our shareholders' value in the long term. Thank you all. With that, I will now turn the call over to Leon, who will reveal the highlights of our fourth quarter financial results.
Thank you, Wang. I would like to start by highlighting some of the key metrics driving Zepp's development. As Wang mentioned, our full year 2021 revenue was RMB 6.25 billion, representing 1% in comparable revenue growth. Our self-branded products played an important role in our 2021 results, as our full year shipments increased by 60% despite the challenges of surging COVID-19 outbreaks and the chip shortage, which impacted shipments of both our self-branded wearables and Xiaomi wearable products. Although we cannot fully predict how the supply chain issues will evolve, we're hopeful that we'll start seeing improvements in the second half of 2022. While we see net increase in unit shipments of our brands, this growth was offset by a decrease in unit shipments of Xiaomi wearable products.
Xiaomi remains as our valued partner, and our Mi Band still ranked number one in market share with 35.6% of the total global smart band market. At the same time, we're also excited to expand and diversify our business and build our own brands with the goal of achieving sustainable long-term growth. Total revenue in Q4 was RMB 1.7 billion, representing a nominal year-over-year decrease of 15.8%. Again, this decrease was mostly driven by the decrease in Mi Band sales. In the meantime, COVID-19 and chip shortages also constrained the growth of our self-branded products. Like many other companies, we have been facing ongoing external challenges since the second half of 2021, many of which still persist today.
COVID-19 not only impacted our sales due to widespread of offline store closures, especially during the holiday seasons, but also dampened our courier services. For example, the January 2022 lockdown of China's Tianjin and Shenzhen ports, which are critical to our global supply chain and product availability, disrupted deliveries and sales worldwide. Moreover, the global semiconductor shortage constrained our supply chain, particularly because many big semiconductor producers are prioritizing the auto industry, EV customers, and the manufacturers. All of these factors negatively influenced our Q4 and full- year 2021 performance, and some continues into 2022. I have to say that we're very proud of our self-branded products growth, especially in light of all these headwinds. Our self-branded products contributed over 47% of total revenue compared to 31% in 2020, as well as over half of our gross profit in fiscal year 2021.
We believe our self-branded products will continue to gain momentum as we further develop our product capabilities and enhance our brand's market recognition globally. Now let's look at gross margin, which can be affected by product mix, product launch timing, and product life cycles, including model upgrades. Our fourth quarter 2021 gross margin was 19.3%, a slight improvement of 30 basis points compared with the same period of 2020. This improvement was supported by refinements of our product mix, including an increasing proportion of self-branded products, which contributed over 60% of total gross profit in Q4. Turning now to costs. Operating expenses have been a key focus of mine since joining the company in the third quarter of 2020, both in terms of absolute numbers as well as percentage of sales.
A portion of operating expenses are fixed, so it takes time and creativity to gradually reduce these expenses. While we have to carefully balance cost controls with expenditures to fuel growth, I'm pleased to report that we have already seen a decreasing trend in total operating expenses since Q3 2020. That will continue to be my focus. Going forward, we'll continue to maintain operating expenses at approximately their current cost level in order to drive profitability. Fourth quarter 2021 operating expenses decreased slightly in absolute terms compared with the same period in 2020. However, at 18.7% of sales, they represented a percentage increase when compared with the fourth quarter of 2020, during which operating expenses were 15.8% of sales.
This was mostly driven by the growth in our sales and marketing expenses in the fourth quarter of 2021, which increased by 30.2% year-over-year, representing 9.2% of sales, compared with 5.9% of sales for the same period in 2020. This relative increase reflects our efforts to fuel growth, including brand- building initiatives such as Up Your Game campaign, designed to drive the global growth of our self-branded Amazfit and Zepp wearables, as well as the launch of our GT 3 series of smartwatches. Furthermore, we carefully manage our research and development costs as well as G&A expenses in the fourth quarter. We're still investing in R&D, sales and marketing, and G&A to support growth, but we have taken a more balanced approach to these expenses.
To that end, R&D expenses were down 27.6% year-over-year, representing 5.6% of sales for the fourth quarter of 2021, compared with 6.6% for the same period last year. This reflects effective expense control in the company's R&D activities, as well as the recognition of certain government subsidies. Our G&A expenses year-on-year is flat, attributed to our effective cost control of operating activities. We'll continue to refine this balanced strategy of supporting our brand building efforts and growth while controlling costs as we progress through 2022.
Next, let's look at net profit, which was lower than last year as a result of higher relative expenses as a percentage of sales, as well as lower other business income due to our RMB 56.5 million partial sell down of our equity stake in [Yueqing], a leading electric toothbrush company, in 2020. Consequently, net income attributed to Zepp Health for the fourth quarter of 2021 was RMB 36 million, compared with RMB 115 million in the fourth quarter of 2020. Thanks to our implementation of more exacting working capital management practices, our balance of cash and cash equivalents remains strong, improving to RMB 1.47 billion as of December 31, 2021. Our working capital ratio also continued to strengthen.a
In 2021, the board approved the deployment of up to $20 million as part of a share repurchase program. So far, we have repurchased $6 million worth of shares. Given our confidence in our growth strategy and financial trajectory, we'll continue with this program. As Wang mentioned earlier, we also announced a one-off dividend program of approximately RMB 40 million, equivalent to 29% of our full year 2021 net income, which we'll fund with our current cash on hand. I would like to finish by addressing some key considerations reflected in our guidance for the first quarter of 2022. The supply chain challenges resulting from chip shortages and delivery uncertainties from the fresh Q1 China's COVID lockdowns caused us to continue to guide conservatively.
In addition, from a seasonality perspective, the first quarter typically generates the lowest level of revenue for the company after the strong holiday season. Consumer anticipation of Xiaomi's new wearable products in the second quarter may negatively impact our Q1 sales. Given the seasonality and supply chain issues I already mentioned, as well as the uncertainties surrounding the conflict between Russia and Ukraine, for the first quarter of 2022, we currently expect net revenues to be between RMB 0.75 billion and RMB 1 billion, compared with RMB 1.15 billion for the first quarter of 2021. Given this outlook, we'll continue to apply 2021's strict cost control measures into 2022.
That outlook is based on our current market conditions and reflects the company's management's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change. This concludes our prepared remarks. We'll now open the call to questions. Operator, please go ahead.
We will now begin the question-and-answer session. To ask a question, you may press star then one on your touch-tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw from the question queue, please press star then two. For the benefit of all participants on today's call, if you wish to ask your question to the company's management in Chinese, please immediately repeat your question in English. At this time, we will pause momentarily to assemble our roster. The first question is from Yayang Luo of Tianfeng Securities. Please go ahead.
Hi. Hi, management. Thank you for taking my question, and congratulations for the fourth quarter. I have two questions. Firstly, about your gross margin. We know since the beginning of the last year, we see semiconductor shortage, as you mentioned. In our coverage, some product companies' gross margin decreased affected by the chip shortage in this quarter. We see Zepp's gross margin increased year-over-year. I think that's beyond my expectation. Can you share some view about the chip shortage impact on your gross margin and any progress about your Huangshan chip? Thank you.
Yeah, no, thank you for the question. On the gross margin, I think the answer is twofold. Number one, we actually proactively change our mix towards proportionally focused on the self-branded products, which carries on average twice the gross margin if we sell a Xiaomi-branded product. Right? If you look at 2020, we have the mix which is more skewed towards 70% of Xiaomi products and 30% of self-branded products. When we end the year of 2021, we're actually hovering around half-half. The self-branded products trend will also continue to grow into 2022. Because of that change, you get a mix improvement on the overall gross margin.
Coming back to your question on the chip shortage, we have announced in the previous quarters that we did certain risk buys ahead of this situation materialize, which also has certain impact on our inventory level. In a mid to short term, we didn't see too much of a material impact on the gross margin because of the risk buy we did. On the Huangshan 2 chip, it's progressing very well according to our schedule. In this year, you will see later this year that there are certain flagship products which we are going to launch as a new product introduction, which will carry the Huangshan 2 chip.
At the same time, we're also going to license a variant of the, like, Huangshan 2 chip to a bigger variety of Chinese watchmakers through our [SiFive] investment, because we licensed this chip also to them. We're also going to get certain profit out of that licensing deal as well.
Okay. A follow-up question about your gross margin. Do you mean your both Xiaomi product and self-brand product to gross margin is decreased, but makes this better in this quarter?
No. I think Xiaomi gross margin has been on a decreasing trend for the company for a few years, right? At least you probably also read the news that Xiaomi is actually targeting a cost to +5%, something like that, right? Xiaomi's gross margin is actually in the low teens, that type of number. That has decreased quarter-over-quarter by 1 percentage point, something like that. Okay. Our self-branded gross margin has been quite strong and hold up over the year.
Okay. My second question about your marketing strategy. The global environment is more uncertain this year. What your marketing strategy changes in this year to, in this global environment now?
Yes. No, I think the short answer to it is no, but we do see the risk of Russia and Ukraine situation, which we also mentioned in our earnings call. We have a strong market share in Russia and Ukraine and all those neighborhood countries. To be honest, Russia and Ukraine's revenue, if I take 2021 full year as the basis, they stand for around 4% of our total revenue, right? That risk we need to manage. In short to midterms, we think we can still manage that risk.
If this war continues into or drags on for a year or two, that definitely will have an impact on our revenue per se. Right? We're slightly different than the other China tech company because majority of our self-branded products are overseas sales. China actually stands for only a small portion of our overall mix. To that end, apart from Russia and Ukraine, our marketing strategy in Western Europe, which is actually a strong foothold of our revenue, and also in United States, didn't change. That will continue to grow.
[crosstalk] Okay. Thank you.
Thank you.
Okay. If you have a question, please press star then one. The next question is from Kevin Xie of China Renaissance. Please go ahead.
Hello. Hi. Thank you, management, for taking my question. I have two questions. Number one will be regarding our newly launched GT 3 series. I was just wondering how the sales do and the sales condition and the general feedback so far is tracking, and how is it matching up to our expectation? Is it better than expected or slightly lagging behind?
Kevin, thank you for your question. Now, on GT 3, as Wang mentioned earlier, is actually a very successful product, and we received a lot of good reviews in China and in overseas market, for this product. If you compare the GT 3 against our own expectation, I think you probably also heard that we are a little bit dampened by the chip shortage and the logistics challenges in Q4. I think we're not in a demand problem, we're more having a supply problem for GT 3. Compared with our own internal expectation, we think we can still do much, much more, but we are actually hurt a little bit by the COVID logistic disruptions in Q4, and that also continues a little bit into Q1.
If you ask me if the product is a big success, I think the product is really a big success, and we, through the launch of the GT 3, we also see that we have the room to improve our ASP further in not only in China, but also in overseas market. That will also, in the longer run, help us to lift our gross margin of the company.
Right. Thank you. Yeah. Just a quick follow on that. I think previously, the Chairman just mentioned that the GT 3 series is being under review for China's NMPA, just for, I guess this is for qualification for more medical application kind of use. I was just wondering, do we have a expectation of approximate timeline of how this review might turn out? Once we obtain this kind of approval, would this enable a new business opportunity in the GT series?
Yes, for sure. We also mentioned that we're not only doing it for the Chinese market, we're also doing it for the European markets and also for the U.S., right? We're actually doing the certification at multiple geographies at the same time. It's related to the blood pressure measurement, which you can measure your blood pressure using our GT 3 watch, which we think is actually a very unique and elegant solution compared with our competitors, right? Yes, the Chinese review I think is going to be a much shorter timeline because it's just going to be a software and algorithm certification. We expect that approval should be able to obtain by somewhere in the course of this year.
The CE and the FDA review might take a little bit longer, but should not be too much longer. Once we get those certifications, for sure, that will give us an edge on offering new services and also a new unique selling point versus the peers.
Okay. Got it. That's good to hear. My second question is, regarding the European market as well, because I think previously you mentioned the situation in Russia and Ukraine right now. I was just wondering, what about for the rest of Europe, do you see any changes in consumer demand or just, right now we're facing more of a logistical issues for these markets?
Yeah, no. I think apart from Russia and Ukraine, we're actually seeing a very healthy growth for the Western European markets. Needless to say that we are already market leader in countries like Italy and Spain. We're actually expanding very fast in countries like Eastern Europe, for example, Poland, Czech Republic, as well as in the very strong foothold of Western Europe like Germany, U.K., Benelux and Nordics. We still think that there's going to be a lot of potential in Europe for us to grow, because we have different product offerings and we have many exciting product offerings which are targeting more at the sports and outdoor activities, which we're going to launch very soon. Hopefully with this new mix of new product introductions, we're able to grow our European market even bigger than what it is now.
All right. Thank you. Very clear. Thank you.
The next question is from Clive Cheung of Credit Suisse. Please go ahead.
Hi. Thank you, management, for taking my question. My first question is on Xiaomi. Obviously, we continue to see the downtrend there in terms of Xiaomi product shipments. I just want to get a sense of, you know, management view on, specifically on kind of the wristband products. Do you see it as the end of the cycle, or do you think it's just an extension of the replacement cycle that is driving the slowdown of this shipment? The second part to that question is, with our discussion with Xiaomi on the new products, could we get a sense, is that going to be a volume driver that could, you know, bring us back to, you know, previous shipment levels of previous years? It's just a variation of kind of current product types and kind of extending the product type a little bit longer? Thank you. That's my first question.
Okay. Clive, let me just comment on the Xiaomi relationship. You know that we actually sign the Xiaomi contract every three years, and then last year we just renewed the new three-year period. The relationship with Xiaomi is very strong. We actually also have different collaborations with Xiaomi beyond the band and the different algorithms which we're working with them, right? Xiaomi stays as a big shareholder of us, and we have a lot of cooperations with Xiaomi. That's the first thing I can guarantee you, right?
On the Xiaomi new products, since I touched this point, if you read the announcement which Xiaomi also published yesterday of the name change for Zepp Life, we also mentioned that we're going to explore more into the chips for the wearables as well as the use of different algorithms and as well as the new form factor of products. Here, yeah, forgive me, I cannot say too much, but definitely we want to actually drive the Xiaomi sales and continue with this relationship much further than what it is now, right? That's on Xiaomi.
Coming back on the Mi Band and the overall band market decline. I think, yeah, I have mentioned that a few quarters already. We see overall band market as a form factor. The market has been in decline for a few quarters already. Yes, maybe it's coming to an end and it's going to be plateau a little bit. That's what we hope for. I think you are more looking at a flatten out or slightly decline type of situation for the band market. At the same time, as we mentioned, in the earnings release as well, on the specific band market, the market share for Xiaomi band, we stay still at 35%, which is by far crushing every other competitors. Right? I hope this would give you a feeling for what it is.
Yeah. It does. Thank you very much. My second question is on the R&D. Obviously, we've toned it down a little bit as a percentage of revenue. I would just like to ask is do you think the kind of toning down was because it was elevated in prior years or and in fact does that you know obviously one of our key advantages or key competitive advantages is, you know, in our research in developing those kind of healthcare kind of chipsets. Does this impact going forward our kind of research levels? Thank you.
No, I think yes, R&D, it's very much linking to the new product introduction as well, right? In different years, we have different cadence on when we release our new product. For example, Q3 2020 was a very new product introduction rich type of quarter, then our R&D expenses in that quarter was extremely high, right? Since we didn't have too much of new product launch in Q4, in essence, GT 3 was the only one which we pushed out in Q4 2021. That's why also R&D expenses by nature is also relatively lower compared with the same period last year. Right?
On the other hand, we also ask the team to do and look at the return on investment on R&D development. Instead of doing everything, and then in the end, it's become a waste, we're more prioritizing our R&D activities and using modularization, the Lego- block- type of approach to do the R&D activities more effectively. That also is one of the main lever whereby we can actually keep our competitive advantage while at the same time keeping the cost under control. Right?
If you actually pull a line on R&D expenses as a percentage of sales for the overall company, I think we stay as an R&D-driven company because the R&D expenses as a percentage of sales for the whole year, if you divided that by our sales, it's actually by far the highest among the selling expenses and G&A expenses. We're still spending roughly around 8%-9% of sales on R&D activities, although it's going to be up and down in different quarters. If you pull it a line, I think we still have that edge versus the other company.
Okay. Thank you very much. I actually just have one question on the COVID impact. I was wondering, it's more forward-looking or fourth- quarter- related. In the first quarter or in the recent weeks, has there been any impact to our manufacturing capacity g iven that—
Yeah. No, Clive, you're very sharp on this. Now, COVID actually posed a lot of uncertainties and negatively impacted on our results, right? In Q4, the sudden lockdown in a lot of European countries around the holiday seasons actually dampened our sales in the offline channel, right? That also plays into why our numbers in Q4 was weaker than what we originally anticipated, right? On the other hand, COVID also create a lot of logistical nightmares for our supply chain. For example, especially, and that's also one of the reasons why we guide the Q1 sales number in a very conservative way, right?
Because, like, as all the other Chinese companies, our export route is actually through Shenzhen into Hong Kong, and then from Hong Kong goes to everywhere in the world, right? With the sudden lockdown in Shenzhen and all the logistics flow also stopped, that actually posed a lot of logistics challenges and supply chain nightmares to our team. That's why we kind of guided a relatively lower number on our guidance for Q1. Yes, COVID definitely has an impact. In the past, it was more on the overseas market. Now if I look at Q1, Q2, the zero COVID policy in China definitely actually disrupted the supply chain and the manufacturing a little bit for us.
As I said, also our supply chain team is looking for other different ways to resolve the situation. That's obviously going to take time and then would have played into some more conservativeness in our guidance going forward. We think this situation should be much better as we enter the second half of this year.
Okay. Thank you very much. Very clear. Thanks again.
The next question is from Andre Lin of Citi. Please go ahead.
Thank you for taking my question. I have a follow-up question on the previous supply- chain- related questions. You mentioned there is a semiconductor supply challenge. Can you give us a color on how the situation is going, and when do you expect the semiconductor supply chain will be resolved, this year or next year? Thank you.
No, Andre, I think I have mentioned it in the script earlier. We think going into the second half of 2022, the situation should be resolved or much better than what it is right now. Q4 was very serious, and then we did certain risk buys, and we did certain commitments. We're putting a lot of chips. And that's after a month or two, I think Q1, on certain product types we don't have a shortage issue. On the other hand, you will see that also more semiconductor companies are prioritizing their chips towards the EV players. That will have certain impact into Q2 as well. We're more constrained by the supply rather than by the demand situation. Based on the current information I have on hand, it looks like by end of Q2, so from May onwards, this situation should be resolved to a much extent.
Thank you. That's very clear. I have a follow-up question is regarding the first quarter guidance. Can you give us a bit more color on the shipment or revenue guidance for the self-brand products on top of the guidance you gave?
We are hurt by a lot of uncertainties in Q1, so it's really a difficult quarter. That's why we guided in a very conservative way, right? I think you also see a lot of companies because of this, they even stop giving the guidance. Okay, we still trying to give a range, although this range is a much wider range, right? There are a few issues. Number one is what I mentioned before on the lockdown of Shenzhen for the upcoming seven days, right? If that seven days is going to continue into 14 or 21 days, right? Nobody knows. Because of that lockdown, manufacturing is stopped. Logistics is stopped.
You cannot even export the products into Hong Kong. We're looking at other ways, for example, going through Tianjin to export the products out of China, et cetera, et cetera, right? That would definitely have a negative impact in the initial outlook we have on Q1. Actually, the last two weeks in the quarter has always been one of the biggest moment of shipping for us because Q1 has been always a slow quarter, but then towards the end of Q1, the production and shipments start to pick up, right? That actually plays into the relatively conservative outlook for which we issued. Number two is the Ukraine and Russia situation.
As I mentioned that Ukraine and Russia plays around 4% of our overall sales. If you average it out, I think every quarter, depends on the quarter, it's talking about $80 million-$100 million of sales, right? Luckily, we have the first month out and the second, the February sales was kind of somewhere cut to the half. We actually lost one and a half months because of Ruble depreciation and everything else. You need to actually, on an apple- to- apple comparison, strip out the impact on the Southern Russia and Ukraine situation. Although, at the same moment, we're trying to look into different ways in whether or not we can continue sales into Russia, right?
I think the third one is the chip shortage, as I just mentioned and explained many times. These three factors kind of played into the number which we put out here. If the Shenzhen lockdown will be only seven days or even within the seven days, we can continue to manage to export and the shipment, I think will probably end up more towards the high end of the guidance range. If not, I think we're probably just in the middle. That's so much color I can give you.
Thank you. That's very clear. Thank you very much. I have no more questions.
As there are no further questions now, I'd like to turn the call back over to the company for closing remarks.
Thank you once again for joining us today. If you have further questions, please feel free to contact Zepp Investor Relations department through the contact information provided on our website or the Piacente Group, the company's Investor Relations consultant. Thank you.
This concludes this conference call. You may now disconnect your line. Thank you.